Asset profile
LB54640
Peptide
Evidence outlook · lead readout
NCT06046443 · Hypothalamic Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06046443: The study randomized 28 participants among three LB54640 dose groups and placebo, with participants, care providers, and investigators blinded. Its primary endpoint was mean percentage change in BMI at Week 14, but the result has not been reported, so whether the endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.